2. Metabolic Enzyme/Protease
  3. Aminotransferases (Transaminases)
  4. ERG245

ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC50 of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer.

For research use only. We do not sell to patients.

ERG245

ERG245 Chemical Structure

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

ERG245 Related Antibodies

Top Publications Citing Use of Products

View All Aminotransferases (Transaminases) Isoform Specific Products:

View All Isoforms
GPT/ALT GOT/AST

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC50 of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer[1].

IC50 & Target[1]

BCAT1

0.5 nM (IC50)

In Vitro

ERG245 (0.1-10 nM; 10 min) potently and selectively inhibits recombinant human BCAT1 with an IC50 of ~0.5 nM, while showing minimal activity against recombinant human BCAT2[1].
ERG245 (200 μM) reduces IFNγ and granzyme B production in activated human CD8+ T cells from donors[1].
ERG245 (100 μM; 72-96 h) partially inhibits the proliferation of activated human CD8+ T cells, as measured by reduced Weighted Proliferation Index[1].
ERG245 (100 μM; 24 h) increases mitochondrial OXPHOS in activated human CD8+ T cells after 24 hours[1].
ERG245 (400 μM; 60 min) induces a rapid increase in mitochondrial iron levels in activated wild-type Jurkat cells[1].
ERG245 (200 μM) increases cytosolic aconitase 1 (ACO1) activity in activated human CD8+ T cells[1].
ERG245 (200 μM; 24 h) partially prevents the development of a terminally exhausted phenotype in human CD8+ T cells generated via repeated TGF-β-supplemented activation, reducing CD8+ PD-1+ TIM3+ GZMB+ cell frequency and CXCL13 secretion[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ERG245 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Human CD8+ (hCD8+) T cells
Concentration: 100 μM
Incubation Time: 72, 96 h
Result: Reduced the Weighted Proliferation Index of activated hCD8+ T cells significantly, indicating partial inhibition of cell expansion.
In Vivo

ERG245 (5 mg/kg; i.p.; twice daily; 6 days) suppresses CD8+ T cell activation and mitigates disease activity in a murine DSS (HY-116282C)-induced colitis model[1].
ERG245 (5 mg/kg; i.p.; twice daily on days 0, 1, and 2) combined with anti-PD-1 induces complete, durable tumor regressions in 83% of mice in the CT26 syngeneic colon cancer model and enhances the frequency of cytotoxic CD8+ T cells in the CT26 tumor microenvironment[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (female, 18-20 g, acute Dextran sulfate sodium-induced colitis)[1]
Dosage: 5 mg/kg
Administration: i.p.; twice daily; 6 days
Result: Reduced colon mass/length ratio.
Decreased the frequency of activated CD8+ CD25+ T cells in mesenteric lymph nodes.
Animal Model: Balb/c (female, 6-7 weeks old, syngeneic CT26 colorectal cancer)[1]
Dosage: 5 mg/kg (ERG245); 10 mg/kg (anti-PD-1)
Administration: i.p.; twice daily on days 0, 1, and 2 (ERG245); i.p.; on days 0, 4, 7, and 11 (anti-PD-1)
Result: Did not alter tumor growth kinetics or survival as monotherapy.
Resulted in 83% (5/6) complete tumor regression rate when combined with anti-PD-1, compared to 17% (1/6) with anti-PD-1 monotherapy.
Prevented tumor growth after re-inoculation in mice with complete tumor regression, indicating immunological memory.
Molecular Weight

347.20

Formula

C17H15BrO3
Appearance

Solid

Color

White to off-white

SMILES

OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (288.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8802 mL 14.4009 mL 28.8018 mL
5 mM 0.5760 mL 2.8802 mL 5.7604 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8802 mL 14.4009 mL 28.8018 mL 72.0046 mL
5 mM 0.5760 mL 2.8802 mL 5.7604 mL 14.4009 mL
10 mM 0.2880 mL 1.4401 mL 2.8802 mL 7.2005 mL
15 mM 0.1920 mL 0.9601 mL 1.9201 mL 4.8003 mL
20 mM 0.1440 mL 0.7200 mL 1.4401 mL 3.6002 mL
25 mM 0.1152 mL 0.5760 mL 1.1521 mL 2.8802 mL
30 mM 0.0960 mL 0.4800 mL 0.9601 mL 2.4002 mL
40 mM 0.0720 mL 0.3600 mL 0.7200 mL 1.8001 mL
50 mM 0.0576 mL 0.2880 mL 0.5760 mL 1.4401 mL
60 mM 0.0480 mL 0.2400 mL 0.4800 mL 1.2001 mL
80 mM 0.0360 mL 0.1800 mL 0.3600 mL 0.9001 mL
100 mM 0.0288 mL 0.1440 mL 0.2880 mL 0.7200 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ERG245 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ERG245ERG 245ERG-245Aminotransferases (Transaminases)CD8+ T cellsBCAT1BCAT2Jurkat cellsanti-PD-1murine tumor modelscolon cancerTGF-βOXPHOSCT26Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ERG245
Cat. No.:
HY-159730
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.